ProQR Therapeutics (PRQR) Competitors $2.63 +0.04 (+1.54%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends PRQR vs. AVXL, IMNM, KURA, KROS, TYRA, ERAS, CRON, EOLS, DNTH, and RAPPShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics ProQR Therapeutics (NASDAQ:PRQR) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Does the media refer more to PRQR or AVXL? In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 3 articles in the media. Anavex Life Sciences' average media sentiment score of 0.66 beat ProQR Therapeutics' score of 0.13 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PRQR or AVXL more profitable? Anavex Life Sciences has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Anavex Life Sciences' return on equity of -30.64% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-134.31% -71.58% -19.70% Anavex Life Sciences N/A -30.64%-28.23% Do insiders & institutionals believe in PRQR or AVXL? 32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor PRQR or AVXL? Anavex Life Sciences received 100 more outperform votes than ProQR Therapeutics when rated by MarketBeat users. Likewise, 74.44% of users gave Anavex Life Sciences an outperform vote while only 61.64% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformProQR TherapeuticsOutperform Votes33161.64% Underperform Votes20638.36% Anavex Life SciencesOutperform Votes43174.44% Underperform Votes14825.56% Which has more volatility and risk, PRQR or AVXL? ProQR Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Do analysts rate PRQR or AVXL? ProQR Therapeutics presently has a consensus price target of $7.60, indicating a potential upside of 188.97%. Anavex Life Sciences has a consensus price target of $43.00, indicating a potential upside of 398.26%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has higher earnings and valuation, PRQR or AVXL? ProQR Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$17.88M12.01-$30.43M-$0.32-8.22Anavex Life SciencesN/AN/A-$47.51M-$0.50-17.26 SummaryAnavex Life Sciences beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$214.82M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-8.2210.5991.3417.19Price / Sales12.01195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book4.785.104.794.78Net Income-$30.43M$151.51M$120.07M$225.60M7 Day Performance-7.07%-2.15%-1.90%-1.23%1 Month Performance-27.35%-3.14%11.45%3.37%1 Year Performance30.85%11.50%30.63%16.58% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.2298 of 5 stars$2.63+1.5%$7.60+189.0%+34.2%$214.82M$17.88M-8.22180AVXLAnavex Life Sciences3.3412 of 5 stars$9.35+10.5%$43.00+359.9%-2.5%$792.88MN/A-18.3640IMNMImmunome2.561 of 5 stars$12.43-1.2%$28.83+132.0%+33.0%$775.84M$10.13M-1.5540Positive NewsKURAKura Oncology4.4841 of 5 stars$9.92+3.0%$29.38+196.1%-27.0%$771.38MN/A-4.08142KROSKeros Therapeutics3.2934 of 5 stars$18.80-0.2%$81.33+332.6%-49.6%$761.53M$651,000.00-3.61100High Trading VolumeTYRATyra Biosciences2.0686 of 5 stars$14.90-0.3%$31.00+108.1%+2.0%$753.94MN/A-9.2820ERASErasca2.0792 of 5 stars$2.62+2.3%$5.90+125.2%+35.8%$740.75MN/A-3.08126News CoveragePositive NewsCRONCronos Group1.8498 of 5 stars$1.94+0.3%$3.00+55.0%+4.8%$739.75M$87.24M-15.19356News CoverageEOLSEvolus3.8237 of 5 stars$11.50-0.1%$23.00+100.0%+12.5%$728.18M$202.09M-12.73170DNTHDianthus Therapeutics1.3337 of 5 stars$24.31+2.1%$46.43+91.0%+213.2%$719.58M$2.83M-9.5280Analyst ForecastNews CoverageRAPPRapport Therapeutics1.5171 of 5 stars$19.57+4.3%$35.00+78.8%N/A$715.87MN/A0.00N/A Related Companies and Tools Related Companies Anavex Life Sciences Competitors Immunome Competitors Kura Oncology Competitors Keros Therapeutics Competitors Tyra Biosciences Competitors Erasca Competitors Cronos Group Competitors Evolus Competitors Dianthus Therapeutics Competitors Rapport Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRQR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRQR Stock Alerts